Bells Corners, Canada
Bells Corners, Canada

Time filter

Source Type

Zhang L.-J.,Beijing Normal University | Chen H.-L.,Beijing Normal University | Li Z.-F.,Beijing Normal University | Lu Z.-L.,Beijing Normal University | Wang R.,Nordion Inc.
Inorganic Chemistry Communications | Year: 2012

A new [12]aneN 3-based fluorescent sensor 3 has been efficiently synthesized through click chemistry. This sensor demonstrates high selectivity for Zn(II) ions in aqueous solution at pH 7.2, even in the presence of other competitive cations. © 2012 Elsevier B.V.


Wang R.,Nordion Inc. | Billone P.S.,Nordion Inc. | Mullett W.M.,Nordion Inc.
Journal of Nanomaterials | Year: 2013

Nanomedicine, defined as the application of nanotechnology in the medical field, has the potential to significantly change the course of diagnostics and treatment of life-threatening diseases, such as cancer. In comparison with traditional cancer diagnostics and therapy, cancer nanomedicine provides sensitive cancer detection and/or enhances treatment efficacy with significantly minimized adverse effects associated with standard therapeutics. Cancer nanomedicine has been increasingly applied in areas including nanodrug delivery systems, nanopharmaceuticals, and nanoanalytical contrast reagents in laboratory and animal model research. In recent years, the successful introduction of several novel nanomedicine products into clinical trials and even onto the commercial market has shown successful outcomes of fundamental research into clinics. This paper is intended to examine several nanomedicines for cancer therapeutics and/or diagnostics-related applications, to analyze the trend of nanomedicine development, future opportunities, and challenges of this fast-growing area. © 2013 Ruibing Wang et al.


Zhu X.,Yanshan University | Pei L.,Yanshan University | Zhao Z.,Yanshan University | Liu B.,Yanshan University | And 2 more authors.
Journal of Alloys and Compounds | Year: 2013

A systematic investigation was performed on the hydrogen storage properties of composites which were prepared by ball milling MgH2 with different amounts of LaH3 and the catalysis mechanism of La hydride on MgH 2 was reported in this paper. Pressure-Composition-Temperature (P-C-T) curves showed that the reversible hydrogen storage capacity of MgH 2 + 20 wt.% LaH3 composite was 5.1 wt.% at 548 K, while the pure MgH2 hardly released any H2 under the same conditions. The addition of LaH3 also significantly improved the hydriding/dehydriding kinetics, and led to the rate-controlling steps of MgH2 becoming altered from a three-dimensional interfacial reaction to a one-dimensional diffusion process. The XRD pattern indicated that the LaH3 phase partially transformed to LaH2.3 phase during the dehydriding process. TEM micrograph images revealed that the LaH 2.3 phase was distributed homogeneously throughout the Mg phase and that the Mg crystals were coated with LaH2.3 crystals in the matrix. This microstructure exhibited an obvious volume contraction and resulted in a distinct strain of MgH2 when the LaH3 phase released H2. DSC curves proved that the addition of LaH3 could decrease the temperature at which the onset of the dehydrogenation of MgH 2 occurred by approximately 20.4 K. © 2013 Elsevier B.V. All rights reserved.


Patent
Nordion Inc. | Date: 2012-05-21

A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q^(1), X, Y, Z, Z^(1), m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a metal ion, such as an ion of ^(90)Y, ^(111)In or ^(177)Lu; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate. A method of therapeutic treatment of a mammal involving administration of the pharmaceutical composition is also described.


The present application discloses a compound of formula (I) or (II):


An isolated conformational isomer of a bifunctional chelating agent of the formula (I): wherein the variables Q^(1 )and Q^(2 )are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a stable or radioactive metal; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate.


Patent
Nordion Inc. | Date: 2013-09-30

A radiation detector that can be used to detect the intensity of radiation fields and provide feedback to the user about the location of radiation fields. The radiation detector has a number of radiation detection volumes that are arranged in a staggered pattern relative to a sweeping direction of the radiation detector. The staggered arrangement of the detection volumes allows a large gap-free detection volume that is composed of smaller detection volumes in order to provide adequate sensitivity.


A method of treating an adsorbent for a chromatographic separation. The method involves sonicating particles of an inorganic metal oxide having fragile edges in the absence of any alkylating or acylating agent to form smoothened particles of the inorganic metal oxide and washing the smoothened particles of the inorganic metal oxide to remove fine particulate matter to produce a treated adsorbent. The treated adsorbent can be used in a method of isolating a daughter radioisotope from a daughter radioisotope that is produced from the parent radioisotope by radioactive decay.


News Article | October 31, 2016
Site: www.newsmaker.com.au

Radiopharmaceuticals are the formulations containing radioactive substances called as radioisotopes or radiotracers. Radiopharmaceuticals are intended to administer to the patient by oral route, parenteral route or IV injections or put into the body cavity; depending on the drug being administered. Small doses of radiopharmaceuticals are often used for diagnostic purpose whereas, larger doses are used for therapeutic purpose. As a therapeutic moiety, radiopharmaceuticals can either be administered to the patient per se, such as in case of metastatic prostate cancer treatment where IV injection of Radium-223 chloride is administered to the patient, or it can be given as molecular radiotherapy or radiolabelled antibody where radiotracer is attached to the cell targeting molecule. Radiopharmaceuticals are used to treat conditions such as cancers, hyperthyroidism, dementia, epilepsy etc. Moreover, radiopharmaceuticals serve a vast applications in diagnostics including but not limited to imaging anatomy of the organ, monitoring the function of a specific organ such as heart, liver, thyroid glands, bones etc. Diagnostic radiopharmaceuticals are largely being used in techniques such as Single-photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET). According to World Nuclear Association, the number of nuclear procedures performed in U.S. in 2012 were recorded as 20 million while that in Europe was 10 million and is projected to increase by 10% by 2017. Radiopharmaceuticals when used as a diagnostic agents are called as radioactive tracers, which emit the radiations from within the body which can be continuously collected externally and monitored over a period equal to shelf life of a tracer. Some of the commercially available radiopharmaceuticals include Metastron (Strontium-89), Xofigo (Radium-223), Quadramet (samarium 153), Amyvid (Fluorine-18), ProstaScint (Indium-111), Glofil-125 (Iodine-125), Cardiogen-82 (Rubidium-82), Ceretec (Technetium-99m), Zevalin (Yttrium-90) and others. Increasing number of nuclear procedure owing to growing prevalence of cancer, bone and heart diseases is the major driver for the growth of global radiopharmaceuticals market. According to World Nuclear Association, more than 10,000 hospitals across the world are using radioisotopes for the diagnostic purpose. Moreover, advances in nuclear imaging technology, increased usage of SPECT and PET imaging techniques, thriving demand for targeted cancer treatment are the factors fueling the growth of global market for radiopharmaceuticals over the forecast period of 2016-2026. However, side effects associated with the use of radiopharmaceuticals, stringency in regulations and high cost of a treatment are the factors hindering the growth of global radiopharmaceuticals market. The global radiopharmaceuticals market has been classified on the basis of product type, application, end user and geography. Based on product type, the global radiopharmaceuticals market is divided into following: Based on the application, the global radiopharmaceuticals market is divided into following: Based on the end user type, the global radiopharmaceuticals market is divided into following: Technetium-99 is the most widely used radiotracer in the diagnostic procedures and thus holds the maximum market share in the global radiopharmaceuticals market. According to International Atomic Energy Agency, each year more than 80% of the total nuclear diagnostic procedures performed worldwide use Technetium-99 as a radiotracer and is predicted to maintain its share over the forecast period due to abundant availability of the molybdenum-99 as a starting material. On the basis of application, diagnostic radiopharmaceuticals segment dominates the global market for radiopharmaceuticals owing to development of new and efficient techniques over the conventional diagnostic methods. In spite of comparatively less use of radiopharmaceuticals as a therapeutic agents, emergence of new effective procedures employing nuclear medicine is expected to fuel the growth of the therapeutic radiopharmaceutical application segment. Geographically, global radiopharmaceuticals market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan and Middle East & Africa. North America holds the largest share in the global radiopharmaceuticals market owing to advancement in healthcare infrastructure, followed by Europe. APEJ market for radiopharmaceuticals is expected to get the traction during the forecast period due to expanding adoption of hospital-based cyclotron for the commercial production of radionuclides. New indications of radiopharmaceutical agents such as FDDNP, FDOPA and novel radiotracers such as FAZA are expected to be launched in the market during the forecast period which will boost the growth of global radiopharmaceuticals market. Some of the key players in radiopharmaceuticals market include Kimberly-Clark Corporation, Eli Lilly and Company, Lantheus Medical Imaging Inc., Ampio Pharmaceuticals Inc., GE Healthcare, Piramal Imaging, Covidien Plc., Cardinal Health, Iso Tex Diagnostics, Inc., Jubilant DraxImage Inc., Bayer HealthCare Pharmaceuticals Inc., Bracco Diagnostic Inc., Navidea Biopharmaceuticals, Nordion Inc., Spectrum Pharmaceuticals, Inc., Mallinckrodt Plc., Bio-Nucleonics Inc., IBA-Molecular, Eczac?ba??-Monrol Nuclear Products, Advanced Accelerator Applications etc.


News Article | November 7, 2016
Site: www.newsmaker.com.au

The Global Nuclear medicine market has been estimated to be valued at USD 11.04 Billion for the year 2015 and the market is expected to hit USD 19.4 billion by the year 2020 at a CAGR of 12.3%. The market is set to be mostly driven by the therapeutic radio pharmaceuticals, which are expected to grow at CAGR of 30% during 2015 to 2020. Though in existence since the 1940s the nuclear medicine market came to the forefront only in the past decade mostly due to the emergence of new radio nucleotides and the number of products under development has grown since then, at an increasing pace. Nuclear medicine has applications in the fields of cardiology, lymphoma, thyroid, neurology oncology, and others.  Increasing incidences of cancer and cardiac ailments, Increasing awareness for radiopharmaceuticals, and ready availability of radiopharmaceuticals are the major driving forces for this market. Increased public awareness and use of Radio diagnostic techniques such as SPECT and PET also fuel the market growth. Some of the major constrains for the market are shorter half- life of radioisotopes, high capital investment, regulatory guidelines and reimbursement issues.  The radiopharmaceutical market is broadly classified into two segments, namely diagnostic and therapeutic. Diagnostic radioisotope segment is sub-divided into SPECT isotopes (Technetium-99m (TC-99m), Thallium-201 (TL-201), Iodine (I-123) and Gallium) and PET radioisotopes (Fluorine-18, Rubidium-82 (RB-82)). Therapeutic radioisotopes segment is divided into Alpha emitters (Radium-223), Beta Emitters (Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (iodine-125, Cesium-131, Palladium-103, & Iridium-192). Diagnostic radioisotopes segment holds the largest share in Nuclear Medicine Radioisotopes Market  Based on geography, the market is segmented into North America, Europe and Asia-Pacific and Rest of the World. North America is the dominant market for diagnostic radioisotopes. Within North America, USA is the largest consumer market for radioisotopes and Canada is the largest producer of Tc-99m. Germany is the largest consumer market for radiopharmaceuticals in the Europe. India and China hold a potential market for radioisotope due to rising healthcare requirement both diagnostic and therapeutic leading to an increase in demand for different radioisotopes in various treatments and applications  Many players in this market are trying to expand their product portfolio in order to top the global market. Few companies adopted product innovation and new product launches as its key business strategy to ensure its dominance in this market. Some of the major players in the radiopharmaceuticals market are Covidien Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion Inc. (Canada), and Siemens Healthcare (PETNET) (Germany).  Key Deliverables in the Study  1. Market analysis for the Global Nuclear medicine market, with region specific assessments and competition analysis on global and regional scales  2. Market definition along with the identification of key drivers and restraints  3. Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale  4. Extensively researched competitive landscape section with profiles of major companies along with their market shares  5. Identification and analysis of the macro and micro factors that affect the Global Nuclear medicine market on both global and regional scales  6. A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information  7. A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market  8. Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped 1. Introduction      1.1 Study Deliverables      1.2 Market Definition      1.3 Sizing Units      1.4 Base Currency      1.5 Review and Forecast Period Years      1.6 General Study Assumptions  2. Research Methodology  2.1 Introduction  2.2 Analysis Methodology  2.3 Econometric Forecast Model  2.4 Research Assumptions  3. Executive Summary  4. Key Inferences  5. Market Overview and Industry Trends  5.1 Current Market Scenario  5.2 Applications of Nuclear Medicine  5.3 Technology Overview  5.4 New Developments  5.5 Investment Analysis  5.6 Porter’s Five Forces  5.6.1 Bargaining Power of Suppliers  5.6.2 Bargaining Power of Consumers  5.6.3 Threat of New Entrants  5.6.4 Threat of Substitute Products and Services  5.6.5 Competitive Rivalry within the Industry  6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)      6.1 Market Drivers  6.1.1 Increasing Incidents of Cancer and Cardiac Ailments  6.1.2 Increasing SPECT AND PET applications  6.1.3 Growing Public Awareness for healthcare      6.2 Market Restraints  6.2.1 Short Half-life of Radiopharmaceuticals        6.2.2 High Capital Investment        6.2.3 Regulatory Guidelines        6.2.4 Reimbursement      6.3 Key Challenges      6.4 Current Opportunities in the Market        6.4.1 Increasing Imaging Technologies        6.3.2 Potential Radioisotopes in Pipeline        6.3.3 Increasing Neurological Applications        6.3.4 Cyclotron based production  7. Market Segmentation By type of Radioisotopes  Diagnostic Radioisotopes  SPECT radioisotopes  Technetium-99m (TC-99m)  Thallium-201 (TL-201)  Iodine (I-123)  Gallium  PET radioisotopes  Fluorine-18  Rubidium-82 (RB-82)  Therapeutic radioisotopes  Alpha emitters  Radium-223  Beta Emitters  Iodine-131  Samarium-153  Lutetium-177  Yttrium-90  Brachytherapy  Iodine-125  Cesium-131  Palladium-103  Iridium-192  GLOBAL MARKET SEGMENTATION BY APPLICATION  Cardiology  Lymphoma  Endocrinology  Neurology  Oncology  Others  By geography  North America  7.4.1.0 Introduction  7.4.1.1 US  7.4.1.2 Canada  7.4.1.3 Mexico  7.4.2 Europe  7.4.2.0 Introduction  7.4.2.1 France  7.4.2.2 UK  7.4.2.3 Germany  7.4.2.4 Italy  7.4.2.5 Spain  7.4.3 Asia-Pacific  7.4.3.0 Introduction  7.4.3.1 India  7.4.3.2 China  7.4.3.3 Japan  7.4.3.4 Australia  7.4.3.5 South Korea  7.4.4 Middle-East and North Africa (MENA)  7.4.4.1 Introduction  7.4.4.2 GCC  7.4.4.3 Egypt  7.4.4.4 Algeria  7.4.5 South America  7.4.5.1 Introduction  7.4.5.2 Brazil  7.4.5.1 Argentina  7.4.5.4 Others  8. Competitive Landscape  8.1 Mergers & Acquisitions  8.2 New Product Launches  8.3 Expansion  8.4 Collaborations  8.5 Market Share Analysis  8.6 Price Value Analysis  9. Company Profiles  9.1 Covidien Plc  9.2 GE Healthcare  9.3 IBA Group  9.4 Lantheus Medical Imaging, Inc.  9.5 Nordion Inc.  9.6 Siemens Healthcare  10. Analyst Outlook for Investment Opportunities  11. Future Outlook of the Market

Loading Nordion Inc. collaborators
Loading Nordion Inc. collaborators